角质形成细胞癌的免疫治疗:流行病学、危险因素、发病机制与管理
本文综述免疫系统在角质形成细胞癌(KC,含鳞状与基底细胞癌)监视与控制中的作用,汇总其免疫相关流行病学、危险因素及免疫治疗管理的最新数据,并强调跨学科协作评估疗效与早期识别免疫相关不良事件以优化患者结局。
要点
- 免疫系统在KC监视与控制中起重要作用,新的免疫疗法已可用于KC。
- 综述汇总KC免疫相关流行病学、危险因素及免疫治疗管理的最新数据。
- 跨学科协作评估免疫治疗反应并早期识别免疫相关不良事件有助于优化结局。
核心结论
- 免疫系统在角质形成细胞癌的监视和控制中起重要作用,新的免疫疗法近期已可用。
研究设计与样本
- 综述,总结KC免疫治疗的关键概念及免疫系统中攻击KC的重要细胞组分,并回顾KC流行病学、危险因素与免疫治疗管理的最新数据。
主要发现
- 综述指出免疫系统在KC监视与控制中作用重要,且免疫治疗领域正在快速演变。
临床怎么用
- 患者会向皮肤科医生咨询免疫治疗为何对KC有效以及是否适用于不同临床场景。
- 与不同学科医学同事协作评估KC对免疫治疗的反应并早期识别免疫相关不良事件,有助于优化患者结局。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The important role of the immune system in the surveillance and control of keratinocyte cancers (KCs), namely squamous and basal cell carcinomas, is increasingly appreciated, as new immunotherapies have recently become available. As the field of immunotherapy is rapidly evolving, this review synthesizes key concepts and highlights important cellular components within the immune system responsible for attacking KCs. We review the most current data on the epidemiology, risk factors, and immunotherapy management for KCs. Patients will seek advice from dermatologists to help explain why immunotherapies work for KCs and whether they might be appropriate for different clinical scenarios. Collaboration with medical colleagues across different disciplines to evaluate KCs for response to immunotherapy and early recognition of immune-related adverse events will help to optimize patient outcomes.
引用
- Neuner RA, Lee J, Rieger KE, et al. Immunotherapy for keratinocyte cancers. Part I: Immune-related epidemiology, risk factors, pathogenesis, and immunotherapy management of keratinocyte cancers. J Am Acad Dermatol. 2023. PMID: 37268390. doi:10.1016/j.jaad.2022.06.1206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。